Literature DB >> 10580418

Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets.

C Pupilli1, S Giannini, P Marchetti, R Lupi, A Antonelli, F Malavasi, S Takasawa, H Okamoto, E Ferrannini.   

Abstract

The type II transmembrane glycoprotein CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) has been proposed as a mediator of insulin secretion from pancreatic beta-cells and as a candidate for autoimmune reactions in type 2 diabetes. We evaluated the presence of anti-CD38 autoantibodies in Caucasian patients with diabetes and investigated the effect of these antibodies on insulin secretion from isolated human pancreatic islets. The presence of anti-CD38 autoantibodies was evaluated by using Western blot analysis in 236 patients with type 2 diabetes (mean age 63 years), in 160 patients with type 1 diabetes (mean age 38 years), and in 159 nondiabetic subjects. Anti-CD38 autoantibody titers at least 3 SD above the mean value of the control group were found in 9.7% of type 2 diabetic patients and in 13.1% of type 1 diabetic patients (chi2 = 15.9, P = 0.0003 vs. 1.3% of control subjects). No significant differences were observed in sex distribution, current age, age at diabetes onset, BMI, fasting serum glucose, or glycemic control between anti-CD38+ and anti-CD38-diabetic patients in either the type 2 or type 1 diabetic groups. The effect of 23 anti-CD38- and 13 anti-CD38+ sera on insulin secretion at low (3.3 mmol/l) or high (16.7 mmol/l) medium glucose concentrations was evaluated in isolated human pancreatic islets. Data are medians (interquartile range). The anti-CD38+ sera potentiated insulin release both at low [95 (64) vs. 23 (12) microU/ml of control incubations, respectively, P < 0.0001] and high [271 (336) vs. a control of 55 (37) microU/ml, respectively, P = 0.001] medium glucose concentrations, whereas the anti-CD38- sera did not. Furthermore, in the pooled data from all 36 tested sera, insulin levels in the islet incubation medium were directly related to the anti-CD38 antibody titer. We conclude that autoantibodies to CD38 are associated with both type 1 and type 2 diabetes in Caucasian subjects. These autoantibodies exert a stimulatory effect on insulin secretion by cultured human islets. The role of this autoimmune reaction in the pathogenesis of diabetes remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580418     DOI: 10.2337/diabetes.48.12.2309

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

1.  Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease.

Authors:  A Antonelli; P Fallahi; C Nesti; C Pupilli; P Marchetti; S Takasawa; H Okamoto; E Ferrannini
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  An emerging role for NAADP-mediated Ca2+ signaling in the pancreatic β-cell.

Authors:  Abdelilah Arredouani; A Mark Evans; Jianjie Ma; John Parrington; Michael X Zhu; Antony Galione
Journal:  Islets       Date:  2010-09-01       Impact factor: 2.694

3.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

Review 4.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

5.  Expression of CD38 with intracellular enzymatic activity: a possible explanation for the insulin release induced by intracellular cADPR.

Authors:  Yasuhiko Ohta; Akira Kitanaka; Keichiro Mihara; Osamu Imataki; Hiroaki Ohnishi; Terukazu Tanaka; Tomohiko Taminato; Yoshitsugu Kubota
Journal:  Mol Cell Biochem       Date:  2011-03-09       Impact factor: 3.396

6.  Antibody-mediated retinal pericyte injury: implications for diabetic retinopathy.

Authors:  Yan Li; Dawn Smith; Qing Li; Nader Sheibani; Suber Huang; Timothy Kern; Ram H Nagaraj; Feng Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-13       Impact factor: 4.799

7.  Involvement of autoimmunity to REG, a regeneration factor, in patients with primary Sjögren's syndrome.

Authors:  K Yoshimoto; T Fujimoto; A Itaya-Hironaka; T Miyaoka; S Sakuramoto-Tsuchida; A Yamauchi; M Takeda; T Kasai; K Nakagawara; A Nonomura; S Takasawa
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

Review 8.  Anti-CD38 autoantibodies in type? diabetes.

Authors:  Roberto Mallone; Paolo Cavallo Perin
Journal:  Diabetes Metab Res Rev       Date:  2006 Jul-Aug       Impact factor: 4.876

9.  Decreased ADP-ribosyl cyclase activity in peripheral blood mononuclear cells from diabetic patients with nephropathy.

Authors:  Michio Ohtsuji; Kunimasa Yagi; Miyuki Shintaku-Kubota; Yukiko Kojima-Koba; Naoko Ito; Masako Sugihara; Naoto Yamaaki; Daisuke Chujo; Atsushi Nohara; Yoshiyu Takeda; Junji Kobayashi; Masakazu Yamagishi; Haruhiro Higashida
Journal:  Exp Diabetes Res       Date:  2009-03-17

10.  Accelerated aging in HIV/AIDS: novel biomarkers of senescent human CD8+ T cells.

Authors:  Jennifer P Chou; Christina M Ramirez; Jennifer E Wu; Rita B Effros
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.